Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | -17.53% | -8.73% | -36.29% |
Mar. 25 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2022 | 861K | Sales 2023 | 107K | Capitalization | 5.8M |
---|---|---|---|---|---|
Net income 2022 | -115M | Net income 2023 | -74M | EV / Sales 2022 | 5.01 x |
Net cash position 2022 | 18.68M | Net Debt 2023 | 5M | EV / Sales 2023 | 101 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.08
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.52% |
1 day | -17.53% | ||
1 week | -8.73% | ||
Current month | -11.54% | ||
1 month | -10.51% | ||
3 months | -18.73% | ||
6 months | -42.21% | ||
Current year | -36.29% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 23-05-15 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 23-05-15 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 21-04-22 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 17-08-31 |
Chris W. Shumway
BRD | Director/Board Member | 58 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.3 | -17.53% | 118,273 |
24-04-23 | 2.789 | +20.73% | 693,546 |
24-04-22 | 2.31 | +3.12% | 25,094 |
24-04-19 | 2.24 | -5.08% | 29,873 |
24-04-18 | 2.36 | -6.35% | 26,223 |
Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-36.29% | 3.69M | |
+4.09% | 43.84B | |
+46.40% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- FNCH Stock